Forum on Regenerative Medicine at the National Academies Releases Perspective Paper on Cell Therapy Manufacturing

The Forum on Regenerative Medicine at the National Academies of Science, Engineering and Medicine released today a perspective discussion paper on cell therapy manufacturing. The discussion paper, titled “Manufacturing Cell Therapies: The Paradigm Shift in Health Care of This Century,” can be accessed through the National Academy of Medicine perspectives page. It discusses challenges, issues

From Boston, ISSCR rounds off its 15th Annual Meeting, and looks to Melbourne

On Saturday, June 17th, the International Society for Stem Cell Research concluded its 15th Annual Meeting. Taking place at the Boston Convention and Exhibition Center in Boston, MA, the meeting saw over 4,000 delegates – scientists, researchers, academics, industry and regulatory professionals – connect for over 4 days of networking, workshops, talks and scientific and

Muscling up: Gene that drives development of stem cells and fibroblasts into muscle described

Myoblasts, from which myocytes are derived, regularly undergo fusion – a process essential for muscle formation during development and regeneration. The process has been extensively studied, though while much is known about it, a protein called myomaker (Tmem8c) is the only muscle-specific protein that is described as being absolutely required for this process. Expression of myomaker in

Save the Date: National Academies Workshop on Manufacturing and Quality of Cell Therapies

Dr. Claudia Zylberberg (Akron) will co-chair an upcoming workshop hosted by the Regenerative Medicine Forum at the National Academies of Science, Engineering and Medicine focused on manufacturing and quality aspects in cell therapies. Set to take place on June 26, 2017 in Washington, DC, the workshop will be a public event that will address and discuss challenges

First gene therapy pulled from market

A dichotomy: While efforts to advance new gene therapies to the clinic are progressing at a staggering pace, one drug that had passed such hurdles is now going the opposite direction. Dutch biotechnology company uniQure announced last week it was removing its gene therapy — going by the commercial name Glybera (alipogene tiparvovec) — from the market, by not